查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1703094

2025年游离DNA（cfDNA）检测全球市场报告

Cell Free DNA (cfDNA) Testing Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年无细胞 DNA（cfDNA）检测市场规模将呈指数级增长。到 2029 年，这一数字将成长至 255.6 亿美元，复合年增长率为 23.9%。预测期内的成长可以归因于向个人化医疗的转变、医疗保健基础设施的加强、人口老化和癌症发病率的增加、精准医疗的采用率的提高、对液态切片技术的认识和接受度的提高，以及对 cfDNA 研究的投资和资金筹措的增加。预测期内的主要趋势包括液态切片技术的采用、下一代定序 (NGS) 技术的进步、人工智慧和机器学习在 cfDNA 检测中的整合、照护现场cfDNA 检测的开发以及云端基础的资料储存和分析平台的采用。

预计未来癌症盛行率的上升将推动无细胞 DNA (cfDNA) 检测市场的成长。癌症包括一组复杂的疾病，其特征是体内异常细胞的生长和扩散。这些细胞可以侵入并损害正常组织，如果没有及时治疗，会带来很大的风险。癌症发生率的上升是由于人口老化、生活方式的改变、环境影响以及检测和诊断方法的进步等因素造成的。 cfDNA 检测可以在早期（通常是在症状出现之前）检测出与癌症相关的基因突变。这种早期检测可以及时干预，并在早期发现癌症，从而改善患者的治疗效果和存活率。例如，世界卫生组织（WHO）在2024年2月预测，到2050年将有超过3500万例新发癌症病例，比2022年预计的2000万例增加77%。因此，癌症盛行率的上升正在推动游离DNA（cfDNA）检测市场的成长。

无细胞 DNA (cfDNA) 检测市场的关键参与者正在优先开发创新技术，例如液态切片测试，以提高检测癌症相关突变和基因改变的敏感度、特异性和效率。液态切片测试是一种诊断程序，可帮助肿瘤学家评估癌细胞释放的循环游离 DNA，从而促进个人化的标靶治疗策略。例如，2023年5月，美国生命科学公司美国实验室控股公司（Labcorp）宣布推出Labcorp Plasma Focus，这是一项进行性或转移性固体癌患者量身定制的新型液态切片测试。该测试透过标准抽血来评估癌细胞中的循环游离 DNA (cfDNA)，使其成为一种微创手术，可快速获得结果。该测试透过识别一系列常见癌症（包括非小细胞肺癌、大肠直肠癌、乳癌、食道癌、胃食道交界处癌、胃癌和黑色素瘤）中可临床操作的生物标誌物，提高了精准肿瘤学的可及性。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、感染疾病、地缘政治、新冠疫情、经济復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球游离DNA（cfDNA）检测PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球游离DNA（cfDNA）检测市场：成长率分析
  • 全球游离DNA（cfDNA）检测市场表现：规模与成长，2019-2024年
  • 全球游离DNA（cfDNA）检测市场预测：2024-2029年及2034年规模及成长
  • 全球游离DNA（cfDNA）检测总目标市场（TAM）

第六章市场区隔

  • 全球游离DNA（cfDNA）检测市场（按产品、性能和预测）2019-2024年、2024-2029年、2034年
  • 供体来源的游离DNA
  • 循环游离细胞肿瘤DNA
  • 游离胎儿DNA
  • 全球游离DNA（cfDNA）检测市场（依平台、绩效及预测），2019-2024年，2024-2029年，2034年
  • 次世代定序（NGS）
  • rPCR和多重PCR
  • qPCR和dPCR
  • 其他平台
  • 全球游离DNA（cfDNA）检测市场的应用、绩效及预测（2019-2024年、2024-2029年及2034年）
  • 肿瘤学
  • 非侵入性产前检测（NIPT）
  • 妇科
  • 移植
  • 其他用途
  • 全球游离 DNA (cfDNA) 检测市场细分（按供体来源游离 DNA 类型、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 器官移植监测
  • 检测移植排斥反应
  • 全球游离DNA（cfDNA）检测市场细分（依循环游离肿瘤DNA类型、绩效及预测），2019-2024年、2024-2029年、2034年
  • 癌症检测
  • 微量残存疾病监测
  • 液态生物检体
  • 全球游离DNA（cfDNA）检测市场游离胎儿DNA细分（按类型）、绩效及预测，2019-2024年、2024-2029年、2034年
  • 非侵入性产前检测（NIPT）
  • 胎儿遗传疾病筛检

第七章 区域和国家分析

  • 全球游离DNA（cfDNA）检测市场：按地区、绩效及预测，2019-2024年、2024-2029年、2034年
  • 全球游离DNA（cfDNA）检测市场各国状况、绩效及预测（2019-2024年、2024-2029年及2034年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 无细胞 DNA（cfDNA）检测市场：竞争格局
  • 无细胞 DNA（cfDNA）检测市场：公司简介
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
    • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Illumina Inc.
  • Qiagen NV
  • Exact Sciences Corporation
  • Bio-Techne Corporation
  • Natera Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories Inc.
  • Invitae Corporation
  • Foundation Medicine Inc.
  • Guardant Health Inc.
  • Integrated DNA Technologies Inc.
  • Caris Life Sciences Inc.
  • Twist Bioscience Corporation
  • Adaptive Biotechnologies Corporation
  • Biodesix Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年游离DNA（cfDNA）检测市场：哪些国家将提供新机会
  • 2029年游离DNA（cfDNA）检测市场：细分领域带来新机会
  • 2029年游离DNA（cfDNA）检测市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r29752

Cell-free DNA (cfDNA) testing is a non-invasive diagnostic technique that examines DNA fragments freely circulating in the bloodstream. This testing method is integral to liquid biopsy procedures, enabling the detection and analysis of genetic mutations and alterations without resorting to traditional tissue biopsies.

The primary products within the cell-free DNA (cfDNA) testing market include donor-derived cell-free DNA, circulating cell-free tumor DNA, and cell-free fetal DNA. Donor-derived cell-free DNA originates from transplanted donor organs or tissues and can be found in the recipient's bloodstream. Various platforms are utilized for cfDNA testing, such as next-generation sequencing (NGS), real-time PCR (rPCR) and multiplex PCR, quantitative PCR (qPCR) and digital PCR (dPCR), among others. These platforms are applied across various domains including oncology, non-invasive prenatal testing (NIPT), gynecology, transplantation, and other medical conditions.

The cell-free DNA (cfDNA) testing market research report is one of a series of new reports from The Business Research Company that provides cell-free DNA (cfDNA) testing market statistics, including cell-free DNA (cfDNA) testing industry global market size, regional shares, competitors with a cell-free DNA (cfDNA) testing market share, detailed cell-free DNA (cfDNA) testing market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-free DNA (cfDNA) testing industry. This cell-free DNA (cfDNA) testing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell free dna (cfDNA) testing market size has grown exponentially in recent years. It will grow from $8.74 billion in 2024 to $10.86 billion in 2025 at a compound annual growth rate (CAGR) of 24.2%. The growth in the historic period can be attributed to a rise in the adoption of cfDNA testing in prenatal care, increasing use of cfDNA analysis, growing interest in cfDNA research across various medical fields, and rise in gaining approvals from regulatory bodies.

The cell free dna (cfDNA) testing market size is expected to see exponential growth in the next few years. It will grow to $25.56 billion in 2029 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to a shift towards personalized medicine, enhancements in healthcare infrastructure, aging population and increasing incidence of cancer, increasing adoption of precision medicine, increasing awareness and acceptance of liquid biopsy techniques, and increasing investment and funding in cfDNA research. Major trends in the forecast period include adoption of liquid biopsy technologies, advancements in Next-Generation Sequencing (NGS) technology, integration of AI and machine learning in cfDNA testing, development of point-of-care cfDNA tests, and implementation of cloud-based platforms for data storage and analysis.

The increasing prevalence of cancer is expected to drive the growth of the cell-free DNA (cfDNA) testing market in the future. Cancer encompasses a complex group of diseases characterized by abnormal cell growth and spread in the body. These cells can invade and damage normal tissue, posing significant risks if left unchecked. The rise in cancer prevalence is attributed to factors such as aging populations, lifestyle changes, environmental influences, and advancements in detection and diagnostic methods. cfDNA testing detects genetic mutations linked to cancer at early stages, often before symptoms manifest. This early detection enables timely interventions, enhancing patient outcomes and survival rates by identifying cancer in its initial phases. For example, in February 2024, the World Health Organization (WHO) projected over 35 million new cancer cases by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Hence, the increasing prevalence of cancer is fueling the growth of the cell-free DNA (cfDNA) testing market.

Key players in the cell-free DNA (cfDNA) testing market prioritize the development of innovative technologies, such as liquid biopsy tests that offer heightened sensitivity, specificity, and efficiency in detecting cancer-related mutations and genetic changes. Liquid biopsy tests involve diagnostic procedures enabling oncologists to assess circulating cell-free DNA released by tumor cells, facilitating personalized and targeted therapy strategies. For instance, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences company, introduced Labcorp Plasma Focus, a new liquid biopsy test tailored for patients with advanced or metastatic solid tumors. This test evaluates circulating cell-free DNA (cfDNA) from tumor cells through a standard blood draw, ensuring minimal invasiveness and rapid results. It enhances access to precision oncology by identifying clinically actionable biomarkers across various common cancers such as non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.

In February 2022, Laboratory Corporation of America Holdings (LabCorp), a US-based clinical healthcare company, acquired Personal Genome Diagnostics Inc. for an undisclosed sum. This acquisition positions LabCorp to advance its existing liquid biopsy capabilities and broaden its array of state-of-the-art next-generation sequencing (NGS)-based genomic profiling tools for cancer, positioning it at the forefront of improving patient outcomes. Personal Genome Diagnostics Inc. specializes in precision oncology diagnostics, including cell-free DNA testing technology.

Major companies operating in the cell free DNA (CFDNA) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC

North America was the largest region in the cell-free DNA (CFDNA) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (CFDNA)) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell free DNA (CFDNA) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cell-free DNA (cfDNA) testing market consists of revenue entities earned by providing services such as liquid biopsy for cancer detection and monitoring, transplant rejection monitoring, and non-invasive prenatal testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA (cfDNA) testing market also includes sales of products such as digital PCR systems, automated nucleic acid extraction systems, real-time PCR instruments, and library preparation systems for NGS. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell Free DNA (cfDNA) Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell free dna (cfdna) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cell free dna (cfdna) testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell free dna (cfdna) testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Donor-Derived Cell-Free DNA; Circulating Cell-Free Tumor DNA; Cell-Free Fetal DNA
  • 2) By Platforms: Next Generation Sequencing (NGS); rPCR And Multiplexed PCR; qPCR And dPCR; Other platforms
  • 3) By Application: Oncology; Non-Invasive Prenatal Test (NIPT); Gynecology; Transplantation; Other Applications
  • Subsegments:
  • 1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring; Graft Rejection Detection
  • 2) By Circulating Cell-Free Tumor DNA: Cancer Detection; Minimal Residual Disease Monitoring; Liquid Biopsy
  • 3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT); Fetal Genetic Disorder Screening
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; Agilent Technologies Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cell Free DNA (cfDNA) Testing Market Characteristics

3. Cell Free DNA (cfDNA) Testing Market Trends And Strategies

4. Cell Free DNA (cfDNA) Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cell Free DNA (cfDNA) Testing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cell Free DNA (cfDNA) Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cell Free DNA (cfDNA) Testing Market Growth Rate Analysis
  • 5.4. Global Cell Free DNA (cfDNA) Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cell Free DNA (cfDNA) Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cell Free DNA (cfDNA) Testing Total Addressable Market (TAM)

6. Cell Free DNA (cfDNA) Testing Market Segmentation

  • 6.1. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Donor-Derived Cell-Free DNA
  • Circulating Cell-Free Tumor DNA
  • Cell-Free Fetal DNA
  • 6.2. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Next Generation Sequencing (NGS)
  • rPCR and Multiplexed PCR
  • qPCR and dPCR
  • Other Platforms
  • 6.3. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Non-Invasive Prenatal Test (NIPT)
  • Gynecology
  • Transplantation
  • Other Applications
  • 6.4. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Donor-Derived Cell-Free DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Organ Transplant Monitoring
  • Graft Rejection Detection
  • 6.5. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Circulating Cell-Free Tumor DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer Detection
  • Minimal Residual Disease Monitoring
  • Liquid Biopsy
  • 6.6. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Cell-Free Fetal DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Invasive Prenatal Testing (NIPT)
  • Fetal Genetic Disorder Screening

7. Cell Free DNA (cfDNA) Testing Market Regional And Country Analysis

  • 7.1. Global Cell Free DNA (cfDNA) Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cell Free DNA (cfDNA) Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cell Free DNA (cfDNA) Testing Market

  • 8.1. Asia-Pacific Cell Free DNA (cfDNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cell Free DNA (cfDNA) Testing Market

  • 9.1. China Cell Free DNA (cfDNA) Testing Market Overview
  • 9.2. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cell Free DNA (cfDNA) Testing Market

  • 10.1. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cell Free DNA (cfDNA) Testing Market

  • 11.1. Japan Cell Free DNA (cfDNA) Testing Market Overview
  • 11.2. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cell Free DNA (cfDNA) Testing Market

  • 12.1. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cell Free DNA (cfDNA) Testing Market

  • 13.1. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cell Free DNA (cfDNA) Testing Market

  • 14.1. South Korea Cell Free DNA (cfDNA) Testing Market Overview
  • 14.2. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cell Free DNA (cfDNA) Testing Market

  • 15.1. Western Europe Cell Free DNA (cfDNA) Testing Market Overview
  • 15.2. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cell Free DNA (cfDNA) Testing Market

  • 16.1. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cell Free DNA (cfDNA) Testing Market

  • 17.1. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cell Free DNA (cfDNA) Testing Market

  • 18.1. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cell Free DNA (cfDNA) Testing Market

  • 19.1. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cell Free DNA (cfDNA) Testing Market

  • 20.1. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cell Free DNA (cfDNA) Testing Market

  • 21.1. Eastern Europe Cell Free DNA (cfDNA) Testing Market Overview
  • 21.2. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cell Free DNA (cfDNA) Testing Market

  • 22.1. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cell Free DNA (cfDNA) Testing Market

  • 23.1. North America Cell Free DNA (cfDNA) Testing Market Overview
  • 23.2. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cell Free DNA (cfDNA) Testing Market

  • 24.1. USA Cell Free DNA (cfDNA) Testing Market Overview
  • 24.2. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cell Free DNA (cfDNA) Testing Market

  • 25.1. Canada Cell Free DNA (cfDNA) Testing Market Overview
  • 25.2. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cell Free DNA (cfDNA) Testing Market

  • 26.1. South America Cell Free DNA (cfDNA) Testing Market Overview
  • 26.2. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cell Free DNA (cfDNA) Testing Market

  • 27.1. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cell Free DNA (cfDNA) Testing Market

  • 28.1. Middle East Cell Free DNA (cfDNA) Testing Market Overview
  • 28.2. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cell Free DNA (cfDNA) Testing Market

  • 29.1. Africa Cell Free DNA (cfDNA) Testing Market Overview
  • 29.2. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cell Free DNA (cfDNA) Testing Market Competitive Landscape And Company Profiles

  • 30.1. Cell Free DNA (cfDNA) Testing Market Competitive Landscape
  • 30.2. Cell Free DNA (cfDNA) Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cell Free DNA (cfDNA) Testing Market Other Major And Innovative Companies

  • 31.1. Illumina Inc.
  • 31.2. Qiagen N.V.
  • 31.3. Exact Sciences Corporation
  • 31.4. Bio-Techne Corporation
  • 31.5. Natera Inc.
  • 31.6. Myriad Genetics Inc.
  • 31.7. NeoGenomics Laboratories Inc.
  • 31.8. Invitae Corporation
  • 31.9. Foundation Medicine Inc.
  • 31.10. Guardant Health Inc.
  • 31.11. Integrated DNA Technologies Inc.
  • 31.12. Caris Life Sciences Inc.
  • 31.13. Twist Bioscience Corporation
  • 31.14. Adaptive Biotechnologies Corporation
  • 31.15. Biodesix Inc.

32. Global Cell Free DNA (cfDNA) Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell Free DNA (cfDNA) Testing Market

34. Recent Developments In The Cell Free DNA (cfDNA) Testing Market

35. Cell Free DNA (cfDNA) Testing Market High Potential Countries, Segments and Strategies

  • 35.1 Cell Free DNA (cfDNA) Testing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cell Free DNA (cfDNA) Testing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cell Free DNA (cfDNA) Testing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer